- Home
- MCAH vs OKYO Comparison
MCAH vs OKYO Comparison
Compare MCAH & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCAH | OKYO |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 87.6M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCAH | OKYO |
|---|---|---|
| Price | $10.02 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 1.5K | ★ 64.9K |
| Earning Date | N/A | 07-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.92 | $1.34 |
| 52 Week High | $11.04 | $3.20 |
Technical Indicators
Market Signals| Indicator | MCAH | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 50.69 |
| Support Level | $9.95 | $1.45 |
| Resistance Level | $11.04 | $1.73 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 4.59 | 45.00 |
Price Performance
Historical ComparisonAbout MCAH Mountain Crest Acquisition 6 Corp. Ordinary Shares
Mountain Crest Acquisition 6 Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.